Published in Hepatitis Weekly, March 21st, 2005
The company reported adjusted net income of $1.3 million or $0.03 per diluted share for the second quarter of FY 2005, versus adjusted net income of $2.3 million or $0.05 per diluted share for the second quarter of FY 2004.
The decrease in adjusted net income versus the prior year was primarily due to a $3.7 million decline in ABELCET sales and a $1.5 million decline in royalties, which are predominately made up of royalties from sales of PEG-INTRON.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly